ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

14:20
 
Share
 

Manage episode 304007661 series 1802332
By American College of Cardiology. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.

In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.

Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

118 episodes